Evidence map›Paper›PMID 38216602›Full record

ArticleScientific reports2024

Gonococcal resistance to zoliflodacin could emerge via transformation from commensal Neisseria species. An in-vitro transformation study.

Saïd Abdellati, Jolein Gyonne Elise Laumen, Tessa de Block, Irith De Baetselier, Dorien Van Den Bossche, Christophe Van Dijck, Sheeba Santhini Manoharan-Basil, Chris Kenyon

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Biology of novel LpxC inhibitors forMicrobiology spectrum · 2026
    Article
  9. In Vitro Activity of Zoliflodacin AgainstAntibiotics (Basel, Switzerland) · 2026
    Article
  10. Article
  11. CommensalAnnual review of microbiology · 2025
    Review
  12. Review
  13. Microbiology spectrum · 2025
    Article
  14. Article
  15. Article
  16. International journal of molecular sciences · 2024
    Article
  17. Article
  18. bioRxiv : the preprint server for biology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Saïd Abdellati *STI Unit, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Jolein Gyonne Elise Laumen *STI Unit, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Tessa de BlockClinical Reference Laboratory, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Irith De BaetselierClinical Reference Laboratory, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Dorien Van Den BosscheClinical Reference Laboratory, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Christophe Van DijckSTI Unit, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Sheeba Santhini Manoharan-Basil *STI Unit, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium. sbasil@itg.be.
Chris Kenyon *STI Unit, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0002-2557-8998
Instituut voor Tropische Geneeskunde · BEUniversity of Antwerp · BEUniversity of Cape Town · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the most promising new treatments for gonorrhoea currently in phase 3 clinical trials is zoliflodacin. Studies have found very little resistance to zoliflodacin in currently circulating N. gonorrhoeae strains, and in-vitro experiments demonstrated that it is difficult to induce resistance. However, zoliflodacin resistance may emerge in commensal Neisseria spp., which could then be transferred to N. gonorrhoeae via transformation. In this study, we investigated this commensal-resistance-pathway hypothesis for zoliflodacin. To induce zoliflodacin resistance, ten wild-type susceptible isolates belonging to 5 Neisseria species were serially passaged for up to 48 h on gonococcal agar plates containing increasing zoliflodacin concentrations. Within 7 to 10 days, all strains except N. lactamica, exhibited MICs of ≥ 4 µg/mL, resulting in MIC increase ranging from 8- to 64-fold. The last passaged strains and their baseline were sequenced. We detected mutations previously reported to cause zoliflodacin resistance in GyrB (D429N and S467N), novel mutations in the quinolone resistance determining region (QRDR) (M464R and T472P) and mutations outside the QRDR at amino acid positions 28 and 29 associated with low level resistance (MIC 2 µg/mL). Genomic DNA from the laboratory evolved zoliflodacin-resistant strains was transformed into the respective baseline wild-type strain, resulting in MICs of ≥ 8 µg/mL in most cases. WGS of transformants with decreased zoliflodacin susceptibility revealed presence of the same zoliflodacin resistance determinants as observed in the donor strains. Two inter-species transformation experiments were conducted to investigate whether zoliflodacin resistance determinants of commensal Neisseria spp. could be acquired by N. gonorrhoeae. N. gonorrhoeae strain WHO P was exposed to (i) pooled genomic DNA from the two resistant N. mucosa strains and (ii) a gyrB amplicon of the resistant N. subflava strain 45/1_8. Transformants of both experiments exhibited an MIC of 2 µg/mL and whole genome analysis revealed uptake of the mutations detected in the donor strains. This is the first in-vitro study to report that zoliflodacin resistance can be induced in commensal Neisseria spp. and subsequently transformed into N. gonorrhoeae.

Indexed as

BarbituratesGonorrheaIsoxazolesMorpholinesOxazolidinonesQuinolonesSpiro CompoundsAnti-Bacterial AgentsDNAHumansMicrobial Sensitivity TestsNeisseriaNeisseria gonorrhoeaeAnti-Bacterial AgentsBarbituratesDNAIsoxazolesMorpholinesOxazolidinonesQuinolonesSpiro Compoundszoliflodacin

Identifiers

PMID38216602
PMCPMC10786824
OpenAlexW4390822238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.